Showing 12,141 - 12,160 results of 101,528 for search '(( 2 step decrease ) OR ( 5 ((teer decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.46s Refine Results
  1. 12141

    Image 2_Decreased activity in zebrafish larvae exposed to glyphosate-based herbicides during development—potential mediation by glucocorticoid receptor.pdf by S. Spulber (19335583)

    Published 2024
    “…Taken together, our data indicate that developmental exposure to GBH has more pronounced effects than GLY on behavior at 5 dpf, and that interference with GR-mediated signaling may have a relevant contribution.…”
  2. 12142
  3. 12143

    Proliferative keratinocytes and BrdU-positive label retaining cells are decreased in <i>Med1<sup>epi−/−</sup></i> mice. by Fumihito Noguchi (615295)

    Published 2014
    “…<p>A: Images show representative high-power fields of immunohistochemistry for Ki67 in 6-month-old wild-type and <i>Med1<sup>epi−/−</sup></i> mice keratinocytes in the transitional epidermis and the migrating epithelial tongues on days 1, 3 and 5 after injury. …”
  4. 12144
  5. 12145
  6. 12146

    KO of <i>grp-1</i>, a GEF that stimulates Arf and PIP5K/PPK-1 to increase production of PIP2 substrate for the IIS cascade, provides neuroprotection. by Nazila Tehrani (665802)

    Published 2014
    “…<p>Left: a histogram showing a decrease in neurodegeneration upon KO of <i>grp-1</i> (a second independent cross gave very similar distribution, not shown) **: p<0.05; ***: p<0.01. …”
  7. 12147
  8. 12148
  9. 12149

    Effect of cholinergic antagonists on CA3-CA1 synchronous epileptiform discharges induced in synaptic blockers aCSF. by Olha Zapukhliak (10297334)

    Published 2021
    “…(B) Application of d-tubocurarine blocks CA3-CA1 synchronous epileptiform discharges: (3) burst of discharges in synaptic blockers aCSF, (4) reduction of the discharges after tubocurarine application, (5) epileptiform discharges decrease under tubocurarine application.…”
  10. 12150
  11. 12151
  12. 12152
  13. 12153
  14. 12154

    Expression of SPDEF in TRAMP C2 prostate adenocarcinoma cells decreased cell growth, reduced migration and colony formation on soft agar. by Xin-Hua Cheng (154368)

    Published 2014
    “…<p><b>A</b>. qRT-PCR shows that <i>SPDEF</i> mRNA is increased in SPDEF OE cells (left panel). …”
  15. 12155

    Significantly decreased levels of CD4<sup>+</sup>CD25<sup>+</sup> Treg cells in arthropathic Tax transgenic mice. by Takeo Ohsugi (225723)

    Published 2011
    “…(B) The majority of CD4<sup>+</sup>CD25<sup>+</sup> T cells in non-transgenic mice expressed a high level of Foxp3 (81.2±1.4%), whereas half of CD4<sup>+</sup>CD25<sup>+</sup> T cells in arthropathic Tax transgenic mice did not express Foxp3 (50.2±5.2%) (n = 6 per group), *** <i>P</i><0.001. …”
  16. 12156

    Wounds treated with sDll4-Fc have increased vascular density but decreased vascular maturation in direct proportion to the dosage level. by Alexandre Trindade (187498)

    Published 2012
    “…C,D,E) Representative anti-PECAM and anti-SMA immunofluorescence images of neo-vasculature in granulation tissue of wounds treated with (D) 0,05 mg/kg or (E) 2,5 mg/kg compared with control mice injected with PBS (C), in days 2, 4 and 6. sDll4-Fc therapy leads to decreased smooth muscle cell recruitment and increased vascular density that is directly proportional to the administered dosage. * In graphics represents p<0,05.…”
  17. 12157

    BC−/EC+ exhibited increased end-systolic and end-diastolic volume and decreased left ventricular function 3 weeks post MI. by Simone Gorressen (605474)

    Published 2015
    “…<p>BC−/EC+ exhibited an increase in end-systolic (<b>A</b>) and end-diastolic volume (<b>B</b>), a significantly more pronounced decrease in stroke volume (<b>C</b>) (BC+/EC+ n = 8 and BC−/EC+ n = 5; two-way ANOVA and Bonferroni’s post hoc test or student’s t-test; * p<0.05, ** p≤ 0.01 BC+/EC+ vs. …”
  18. 12158
  19. 12159
  20. 12160

    Supplementary Material for: Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcino... by Arizumi T. (3588833)

    Published 2014
    “…<b><i>Results:</i></b> Statistically significant differences in OS were observed among the three groups (p < 0.001). A decrease or disappearance of arterial enhancement was significantly associated with improved OS compared to patients with no change in arterial enhancement; the median OS was 19.9 months (95% confidence interval, CI, 16.4-24.5 months) and 6.0 months (95% CI, 4.0-8.8 months), respectively (p < 0.001). …”